Invest-in-America
1週前
MGRX: Sorry "BARBIE DOLL", but this guy has sold the most "TOYS" ---
COPILOT SAYS: "How rich is the inventor of Rubik's Cube? The inventor of the Rubik's Cube, Erno Rubik, has an estimated net worth of $100 million to $110 million2. He became a self-made millionaire from the communist block, thanks to the immense success of his invention. Over 350 million Rubik's Cubes have been sold worldwide, making it the best-selling toy of all time1. It's quite an impressive achievement, isn't it?"
BUT THEN, COPILOT CORRECTS ITSELF: "But you just said that RUBIK'S CUBE is the best selling toy of all time!!! You're right, and I apologize for the confusion. While both the Rubik's Cube and Barbie are incredibly popular, they have different claims to fame. The Rubik's Cube is often considered one of the best-selling puzzle toys of all time, with over 350 million units sold. The Barbie doll, on the other hand, has sold over 1 billion units worldwide since its debut and is one of the best-selling dolls of all time. Both have achieved iconic status in the toy industry, each dominating their own category."
KeepItRealistic
2月前
$MGRX excellent exposure to capital
Dallas, Texas--(Newsfile Corp. - October 18, 2024) - Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform,, is pleased to announce it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit, which will be taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 22nd to Wednesday, October 23rd, 2024, in Nassau, Bahamas.
Jacob Cohen, Founder and CEO, is scheduled to present on Wednesday, October 23rd at 11:10 EDT. Jacob will also be fielding investor questions during the summit.
The Centurion One Capital 2nd Annual Bahamas Summit will feature public and private companies across various industries that will be given the opportunity to present to some of the most prominent venture capital, family office, private equity firms, high net worth individuals and institutional investors in the growth space attending from Canada, the United States, and abroad. For registration details, please click here.
Summit Details:
Event: Centurion One Capital 2nd Annual Bahamas Summit
Format: Presentations, Q&A, Panel Discussions and 1 X 1 Investor Meetings
Dates: Tuesday, October 22nd and Wednesday, October 23rd, 2024
Time: 9:00 AM EDT – 4:00 PM EDT
Venue: Rosewood Baha Mar Hotel
About Centurion One Capital
Centurion One Capital (“Centurion One”) is the premier independent Investment Banking firm dedicated to fueling the growth and success of growth companies in North America. With an unwavering commitment to delivering comprehensive financial solutions and strategic guidance, Centurion One is a trusted strategic partner and catalyst to propel issuers to unlock their full potential. Our team comprises seasoned professionals who combine extensive financial expertise with deep knowledge of various sectors. We take a proactive and results-driven approach, working closely with our clients to develop tailored strategies and execute transactions that maximize value and drive long-term success.
Centurion One - Empowering Growth. Driving Innovation. Partnering for Success.
tw0122
2月前
$3.65 + 37% Reverse split and “TRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.
Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, “TRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling appetite. Clinical trials have shown that Tirzepatide can deliver weight reductions of up to 20% in obese individuals. The phase 3 SURMOUNT-1 clinical trial showed that a significant percentage of participants achieved weight loss of over 15-20% in just 72 weeks, marking it as a viable option and alternative for effective, long-term weight management?.
Further, in the SURMOUNT-4 trial, Tirzepatide not only helped patients achieve substantial weight loss, but it also helped patients maintain their progress over an extended period. After 88 weeks of treatment, patients experienced a total weight reduction of up to 25%, with nearly 90% maintaining at least 80% of their initial weight loss?.
MangoRx’s TRIM formulation now provides Tirzepatide treatment in an easy-to-use oral dissolvable tablet, eliminating the need for injections and enhancing patient convenience.
The launch of TRIM is a key strategic move for MangoRx, as the Company looks to strengthen its foothold in the expanding weight management sector. As demand for non-invasive, clinically proven solutions rises, we believe MangoRx is positioned to capitalize on this market growth.
Jacob Cohen, CEO and Founder of MangoRx, stated, “We are excited to bring TRIM to market, offering consumers a cutting-edge, oral alternative to conventional weight loss injections. TRIM’s introduction marks another significant step for MangoRx as we continue to innovate and meet the changing needs of patients. By launching TRIM, we are delivering a solution that enhances patient convenience without sacrificing efficacy. As demand for GLP-1-based treatments continues to climb, our telemedicine platform ensures that patients have access to safe, reliable options.”
According to a study performed by Roots Analysis, the global GLP-1 market is projected to grow from $49.3 billion in 2024 to $157.5 billion by 2035, with the obesity segment expected to capture the majority share by 2035, due to rising obesity rates and demand for effective treatments.
With the addition of TRIM, MangoRx now offers patients both Tirzepatide and Semaglutide options for weight loss treatments. Following the successful release of our Semaglutide-based oral dissolvable tablet branded as SLIM, patients can choose from two advanced, highly effective GLP-1 receptor agonists, each tailored to meet different needs in their weight management journey. Both products are currently listed on the MangoRx website and available with a doctor’s prescription, providing expanded access to cutting-edge weight loss solutions through its telemedicine platform.
KeepItRealistic
3月前
$MGRX mega news below (huge market)
Market Correction incoming…
“Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, “TRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling appetite. Clinical trials have shown that Tirzepatide can deliver weight reductions of up to 20% in obese individuals. The phase 3 SURMOUNT-1 clinical trial showed that a significant percentage of participants achieved weight loss of over 15-20% in just 72 weeks, marking it as a viable option and alternative for effective, long-term weight management?.
Further, in the SURMOUNT-4 trial, Tirzepatide not only helped patients achieve substantial weight loss, but it also helped patients maintain their progress over an extended period. After 88 weeks of treatment, patients experienced a total weight reduction of up to 25%, with nearly 90% maintaining at least 80% of their initial weight loss?.
MangoRx’s TRIM formulation now provides Tirzepatide treatment in an easy-to-use oral dissolvable tablet, eliminating the need for injections and enhancing patient convenience.
The launch of TRIM is a key strategic move for MangoRx, as the Company looks to strengthen its foothold in the expanding weight management sector. As demand for non-invasive, clinically proven solutions rises, we believe MangoRx is positioned to capitalize on this market growth.
Jacob Cohen, CEO and Founder of MangoRx, stated, “We are excited to bring TRIM to market, offering consumers a cutting-edge, oral alternative to conventional weight loss injections. TRIM’s introduction marks another significant step for MangoRx as we continue to innovate and meet the changing needs of patients. By launching TRIM, we are delivering a solution that enhances patient convenience without sacrificing efficacy. As demand for GLP-1-based treatments continues to climb, our telemedicine platform ensures that patients have access to safe, reliable options.”
According to a study performed by Roots Analysis, the global GLP-1 market is projected to grow from $49.3 billion in 2024 to $157.5 billion by 2035, with the obesity segment expected to capture the majority share by 2035, due to rising obesity rates and demand for effective treatments.
With the addition of TRIM, MangoRx now offers patients both Tirzepatide and Semaglutide options for weight loss treatments. Following the successful release of our Semaglutide-based oral dissolvable tablet branded as SLIM, patients can choose from two advanced, highly effective GLP-1 receptor agonists, each tailored to meet different needs in their weight management journey. Both products are currently listed on the MangoRx website and available with a doctor’s prescription, providing expanded access to cutting-edge weight loss solutions through its telemedicine platform.”
KeepItRealistic
3月前
“On October 1, 2024, the Company delivered an Advance Notice to the Purchaser and sold the Purchaser 2,000,000 shares of common stock pursuant to the terms of the ELOC for $0.26 per share for a total of $521,016, net of fees, discounts and expenses”
Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
glenn1919
2月前
Penny chatter
3月前
TrendTrade2016
3月前
FROZENFLAME
4月前
Penny2Dime
5月前
SantaZar
6月前
Golden Cross
7月前
Carjockey2
7月前
crowin
7月前
